Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Day One Biopharmaceuticals (DAWN) EBIT Margin: 2024-2025

Historic EBIT Margin for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to -60.94%.

  • Day One Biopharmaceuticals' EBIT Margin fell 9255.00% to -60.94% in Q3 2025 from the same period last year, while for Sep 2025 it was -123.90%, marking a year-over-year change of. This contributed to the annual value of -165.65% for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its EBIT Margin stood at -60.94% for Q3 2025, which was up 40.92% from -103.14% recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year EBIT Margin high stood at 31.61% for Q3 2024, and its period low was -1,401.45% during Q2 2024.
  • In the last 2 years, Day One Biopharmaceuticals' EBIT Margin had a median value of -118.32% in 2025 and averaged -315.19%.
  • Within the past 5 years, the most significant YoY rise in Day One Biopharmaceuticals' EBIT Margin was 129,831bps (2025), while the steepest drop was 9,255bps (2025).
  • Over the past 2 years, Day One Biopharmaceuticals' EBIT Margin (Quarterly) stood at -223.68% in 2024, then slumped by 9,255bps to -60.94% in 2025.
  • Its EBIT Margin was -60.94% in Q3 2025, compared to -103.14% in Q2 2025 and -133.50% in Q1 2025.